Remove 2014 Remove Healthcare Remove Physicians Remove Safety
article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018. It also raises healthcare costs for public and private insurers alike. In my opinion, PhRMA has zero credibility.

Pharma 255
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Both the physician and the patient have to be registered and the drugs can only come from a primary source through limited distribution. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.

Medical 83
article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Over his career as a physician and scientist he published 108 papers and 49 patents. Injection Safety Fact Sheet. It has potential to be applied simply and directly to most existing commercial vaccines. Since vaccines can now be reformulated to meet the relevant WHO guidelines, the route to a future of fridge-free vaccines is open.

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

There are many challenges in the development of therapies for rare diseases due to several unique factors, including small target patient populations, lack of long-term safety and efficacy data or natural history data, and often complex administration, dosing, and patient monitoring requirements,” Chiesi says. Chiesi’s philosophy in action.

article thumbnail

Private Patient Advocacy: Educating Patients To Be Their Own Advocates With Antra Boyd And Karen DiMarco

Evolve Your Success

We saw poor outcomes and couldn’t figure out how to change it from within so we thought, “If we can walk alongside a patient and help them navigate the healthcare system, maybe they would have better outcomes.” I was done clinical nursing in 2014. Physicians and providers like it because people are engaged in their care.

article thumbnail

Medical Sales In Sterile Processing And Infection Prevention With Mark Copeland

Evolve Your Success

Mark Copeland has an experience in medical device sales with 18 years in the game and 27 in healthcare. Some of his notable achievements were selling the first 7D Navigation and One Tray sterilization system and the first provisional script to over 300 physicians. He brings new products that solve healthcare problems.